食物過敏：市場洞察、流行病學和市場預測（2036 年）

食物過敏的洞察與趨勢

• 根據 DelveInsight 的分析，到 2025 年，主要市場（美國、歐盟 4 國（德國、法國、義大利、西班牙）、英國和日本）的食物過敏市場預計將達到約 35 億美元。
• 食物過敏負擔的很大一部分與氣喘、異位性皮膚炎和過敏性鼻炎等並存的特異性疾病以及兒童的易感性和遺傳因素有關。這凸顯了採取綜合疾病管理、早期診斷和預防策略以減輕嚴重過敏反應並改善患者預後的必要性。
• 治療過敏性休克的首選藥物是腎上腺素。抗組織胺、皮質類固醇和支氣管擴張劑也可以使用，但這些藥物並不能治療過敏性休克本身，只能作為輔助性治療。
• 減敏療法透過提高反應閾值、降低意外過敏反應的風險、增強患者的保護和信心，從而改善食物過敏的治療效果。
• 目前，Omalizumab（XOLAIR）、腎上腺素鼻噴霧（NEFFY）和花生過敏原粉（PALFORZIA）是僅有的已通過核准藥物，可為患者提供重要的治療選擇。 Stallergenes Greer公司將於2026年7月31日停止銷售PALFORZIA。此次自願停產與產品的安全性、品質或有效性無關。
• 在不斷發展的食物過敏治療領域，臨床試驗由 DBV Technologies（Viaskin [DBV712] 花生貼片）、Aravax（PVX108）和 Aquestive Therapeutics（ANAPHYLM（腎上腺素舌下膜））等公司主導。

7個主要國家的食物過敏市場規模及預測

• 預計到 2025 年，食物過敏的市場規模約為 35 億美元。
• 預計到2036年，食品過敏市場規模將達到約105億美元。
• 食品過敏市場成長率（2026-2036 年）：複合年成長率約 9%

這份食物過敏市場報告對當前市場格局進行了全面分析，涵蓋標準治療方案、臨床實踐和不斷發展的治療流程。報告評估了食物過敏患者的負擔趨勢、收入和市場佔有率趨勢、患者佔比尖峰時段以及治療方案的採納率，並對全球市場規模和成長率預測（包括歷史數據和2022-2036年的預測數據）進行了詳細評估。報告重點關注食物過敏領域尚未滿足的關鍵醫療需求，分析了競爭格局和臨床狀況，以識別高價值的成長機會，並對未來的市場成長潛力做出清晰展望。

推動食物過敏市場發展的關鍵因素

食物過敏發生率上升

食物過敏症的日益普遍，尤其是在男性族群中，是推動市場成長的主要因素。根據七國集團（G7）的報告顯示，預計到2025年，確診病例數將達到約6,100萬例。

拓展針對性食物過敏治療的機會

新興證據表明，與傳統的過敏原迴避策略相比，新型免疫療法具有更高的安全性、耐受性和緩解疾病潛力，這為藥物研發人員提供了更多機會，讓他們專注於誘導免疫耐受、降低嚴重反應風險並為食物過敏患者提供長期保護的方法。

食物過敏的理解與治療流程

食物過敏概述

食物過敏是一種免疫介導性疾病，當人體錯誤地將某些食物蛋白識別為有害物質時，就會引發異常的免疫反應。症狀輕重不一，可能包括搔癢、蕁麻疹、腫脹、腹痛、嘔吐和腹瀉。嚴重時，可能發生過敏性休克，伴隨呼吸困難和血壓下降，危及生命。食物過敏主要由接觸常見過敏原引起，例如花生、堅果、牛奶、雞蛋、小麥、大豆、魚類和貝類。食物過敏通常是由遺傳和環境因素共同作用導致的。

食物過敏的診斷

食物過敏的診斷主要依據臨床評估和詳細的病歷。重點在於接觸過敏食物後出現的可重複性症狀，例如蕁麻疹、胃腸道不適、呼吸困難或過敏性休克。雖然皮膚點刺試驗和血清特異性免疫球蛋白E (IgE) 檢測等方法有助於確認過敏反應，但口服食物激發試驗仍是確診的黃金標準。

食物過敏的治療

食物過敏治療的主要目標是預防過敏反應，降低嚴重後果（如過敏性休克）的風險，提高患者的生活品質，並在可能的情況下誘導長期免疫耐受性。治療主要包括嚴格避免接觸過敏原和對患者進行教育，包括仔細標註過敏原資訊和防止交叉污染。做好緊急準備至關重要，腎上腺素（例如Epipen、AUVI-Q）是治療過敏性休克的首選藥物，而抗組織胺（例如西替利嗪、苯海拉明）和皮質類固醇等輔助性治療則用於控制症狀。

在長期管理中，階梯式免疫療法正日益普及。口服免疫療法（OIT），例如帕福齊亞（PALFORZIA），透過控制過敏原暴露來實現脫敏。更新的選擇包括經皮免疫療法（EPIT），例如維亞斯金花生貼片（DBV712），以及安全性較高的舌下免疫療法（SLIT）。對於患有嚴重或多種食物過敏的患者，可考慮引入針對IgE介導路徑的生物製藥，例如奧沙利鉑（XOLAIR），以改善治療效果。支持性治療，包括飲食調整、定期監測和合併過敏性疾病的管理，對於確保持久保護和降低復發風險仍然至關重要。

食物過敏的流行病學

食物過敏流行病學分析和預測的主要發現

• 根據 DelveInsight 的估計，到 2025 年，七大主要國家中被診斷出患有食物過敏症的人數將達到約 6,100 萬人。
• 在歐盟四國和英國中，預計到 2025 年，西班牙確診食物過敏患者人數最多，其次是德國，而法國預計人數最少。
• 到 2025 年，在 700 萬名食物過敏患者中，男性佔 53%，女性佔 47%。
• 2025 年，在日本，雞蛋過敏的診斷盛行率在食物過敏原中最高，其次是牛奶過敏，而魚類過敏的盛行率最低。

食品過敏市場展望

食物過敏市場正經歷重大變革，從嚴格的過敏原規避和緊急應變轉向更積極的疾病修正治療。諸如PALFORZIA、Viaskin花生貼片（DBV712）和PVX108（AVX-201）等新型免疫療法的出現，反映了治療策略正從暫時脫敏轉向靶向免疫調節，旨在誘導長期耐受性。這些進展凸顯了以機制為基礎的策略，這些策略著重於提高安全性、降低嚴重反應風險和增強患者依從性，從而提升了臨床可信度並重塑了市場競爭格局。

隨著PVX108（AVX-201）、Viaskin花生貼片（DBV712）和ANAPHYLM（腎上腺素舌下膜）等創新候選藥物的持續研發，食物過敏的治療格局正在發生變化，與其他免疫介導疾病類似，精準醫療療法正日益受到關注。此外，針對主要免疫路徑的生物製藥，例如XOLAIR，進一步拓展了治療的可能性。目前，美國是全球最大的食物過敏市場，其市場規模超過歐洲和其他地區，這得益於較高的認知度、不斷提高的診斷率、強力的監管支持以及對新療法的早期應用。

總體而言，PALFORZIA等差異化療法的推出，以及Viaskin花生貼片、PVX108和ANAPHYLM等新療法的湧現，加上診斷技術的進步和患者及看護者意識的提高，預計將推動全球食物過敏市場在預測期內穩步成長。這一不斷變化的市場格局為已通過核准的產品和在研候選藥物都帶來了巨大的商業性機遇，隨著該領域在實現長期疾病管理和提高患者生活品質方面取得進展，這種潛力將進一步增強。

• 據估計，到2025年，七大主要國家的食物過敏市場總規模將達到約35億美元，其中美國佔最大佔有率。預計該市場將以較高的複合年成長率成長至2036年。
• 到 2025 年，在歐盟四國和英國中，德國的市佔率最大，其次是英國，而法國的市佔率最小。
• 過敏原特異性免疫療法：諸如「PALFORZIA」和「Viaskin花生貼片（DBV712）」之類的產品旨在透過控制過敏原暴露來使患者脫敏並提高耐受閾值，但必須仔細監測不利事件。
• 生物製藥：諸如「XOLAIR」之類的療法針對 IgE 介導的途徑，可降低過敏反應的嚴重程度，因此正在成為食物過敏治療中的輔助性治療或單一療法選擇。

雖然緊急治療和免疫療法共同構成了目前的標準治療方案，但生物製藥和下一代免疫調節療法正在塑造食物過敏領域未來的創新模式。

目錄

第1章：主要見解

第2章：引言

第3章執行摘要

第4章 主要事件

第5章 食物過敏：流行病學和市場預測的調查方法

第6章 食物過敏：市場概覽

• 新興趨勢分析
• 2025年7個主要國家食物過敏市場佔有率（%）分佈：依治療方法分類
• 2036年7個主要國家食物過敏市場佔有率（%）分佈：依治療方法分類

第7章 食物過敏：疾病背景與概述

• 症狀
• 引起過敏的食物
• 導致食物過敏的風險因素
• 臨床症狀
• 診斷
  • 鑑別診斷
  • 診斷演算法
  • 診斷指南

第8章 治療與管理

• 食物過敏：治療流程
• 食物過敏：治療指南

第9章 食物過敏：流行病學和患者群體

• 前提和基礎
• 食物過敏：7個主要國家的確診病例數
• 美國
  • 食物過敏：美國確診患者總數
  • 食物過敏：美國特異性過敏原確診病例
  • 食物過敏：美國按性別分類的患者診斷盛行率
  • 食物過敏：以嚴重程度分類的美國確診患者人數
  • 食物過敏：美國已治療病例總數
• 歐盟4和英國
  • 歐盟四國和英國確診食物過敏的總數
  • 歐盟四國和英國確診的特異性過敏原食物過敏病例數
  • 歐盟四國和英國按性別分類的食物過敏確診病例數
  • 歐盟四國和英國按嚴重程度分類的已確診食物過敏病例數
  • 歐盟四國和英國接受食物過敏治療的患者總數
• 日本
  • 食物過敏：日本確診患者總數
  • 食物過敏：日本特異性過敏原確診病例
  • 食物過敏：以性別分類的日本確診患者人數
  • 食物過敏：以嚴重程度分類的日本確診患者人數
  • 食物過敏：日本治療總病例數

第10章 食物過敏：患者病情進展

第11章 非處方藥

• 食物過敏：競爭格局
• Omalizumab（XOLAIR）：諾華/羅氏
  • 藥物概述
  • 監管里程碑
  • 其他發展活動
  • 主要臨床試驗概述
  • 臨床開發
  • 分析師意見
• 腎上腺素（NEFFY/EURNEFFY）：ARS Pharmaceuticals/ALK/Alfresa

第12章：新興治療藥物

• 食物過敏：新的競爭格局
• Viaskin (DBV712) 花生貼：DBV Technologies
  • 藥物概述
  • 其他發展活動
  • 臨床開發
  • 分析師意見
• PVX108 (AVX-201)：阿拉巴克斯

第13章 食物過敏：七國集團國家分析

• 食物過敏：市場展望
• 市場預測的關鍵假設
  • 關於成本的假設
  • 價格趨勢
  • 對類似產品的評價
  • 發布年份及療程的普及程度
• 食物過敏：聯合分析
• 食物過敏：市場規模，主要7個國家
• 食物過敏：依治療方法分類的市場規模（主要7個國家）
• 美國
  • 食物過敏：市場規模，美國
  • 食物過敏：依治療方法分類的市場規模（美國）
• 歐盟4和英國
  • 食物過敏：市場規模、歐盟4國和英國
  • 食物過敏：依治療方法分類的市場規模，歐盟4國和英國
• 日本
  • 食物過敏：市場規模，日本
  • 食物過敏：依治療方法分類的市場規模（日本）

第14章 食物過敏：未被滿足的需求

第15章 食物過敏：SWOT分析

第16章 食物過敏：關鍵意見領袖（KOL）

第17章 食物過敏：市場進入與報銷

• 美國
• 歐盟4和英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
• 日本
• 2025年市場進入與定價政策趨勢總結與比較
• 食物過敏：治療藥物的市場進入和報銷

第18章附錄

第19章 DelveInsight 服務

第20章免責聲明

第21章：關於DelveInsight

Food Allergy Insights and Trends

• According to DelveInsight's analysis, the Food Allergy market size was found to be ~USD 3,500 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• A significant proportion of the food allergy burden is associated with comorbid atopic conditions such as Asthma, Atopic Dermatitis, and Allergic Rhinitis, along with pediatric predisposition and genetic factors, highlighting the need for integrated disease management, early diagnosis, and preventive strategies to reduce severe reactions and improve patient outcomes.
• Epinephrine is the first-line treatment for anaphylaxis. Antihistamines, corticosteroids, and bronchodilators may also be used, but they do not treat anaphylaxis itself and serve only as adjunctive therapies.
• Desensitization improves food allergy care by raising reaction thresholds, reducing accidental anaphylaxis risk, and enhancing patient protection and confidence.
• Currently, omalizumab (XOLAIR), epinephrine nasal spray (NEFFY), and peanut allergen powder (PALFORZIA) are the only approved medications offering important treatment options for patients. Stallergenes Greer will discontinue the commercialization of PALFORZIA as of July 31, 2026. This voluntary discontinuation is not related to product safety, quality, or efficacy.
• The evolving food allergy treatment landscape features clinical trials led by DBV Technologies (Viaskin [DBV712] peanut patch), Aravax (PVX108), Aquestive Therapeutics (ANAPHYLM (epinephrine sublingual film)), and others.

Food Allergy Market Size and Forecast in the 7MM

• 2025 Food Allergy Market Size: ~USD 3,500 million
• 2036 Projected Food Allergy Market Size: USD ~10,500 million
• Food Allergy Growth Rate (2026-2036): ~9% CAGR

DelveInsight's 'Food Allergy- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology, as well as the Food Allergy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Food Allergy market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Food Allergy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Food Allergy and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Food Allergy Market

Rising Food Allergy Prevalence

The Rising food allergy prevalence, particularly among males, is a key driver of market growth. In 2025, the 7MM reported approximately 61 million diagnosed prevalent cases.

Rising Opportunities in Targeted Food Allergy Therapies

Emerging evidence of improved safety, tolerability, and potential disease-modifying effects of novel immunotherapies over traditional allergen avoidance strategies highlights a growing opportunity for drug developers to focus on approaches that induce immune tolerance, reduce the risk of severe reactions, and provide long-term protection in food allergy patients.

Emerging Food Allergy Competitive Landscape

The evolving food allergy pipeline is a key market driver, with increasing focus on immunotherapies and novel desensitization approaches. Promising candidates such as DBV712, PVX108 (AVX-201), and ANAPHYLM are advancing through clinical trials, supporting future market growth.

Food Allergy Understanding and Treatment Algorithm

Food Allergy Overview

Food allergy is an immune-mediated condition that occurs when the body mistakenly identifies certain food proteins as harmful, triggering an abnormal immune response. It can range from mild to severe, with symptoms such as itching, hives, swelling, abdominal pain, vomiting, and diarrhea, and in severe cases, anaphylaxis, which may involve difficulty breathing, a drop in blood pressure, and can be life-threatening. Food allergy is primarily caused by exposure to common allergens such as peanuts, tree nuts, milk, eggs, wheat, soy, fish, and shellfish. It typically develops due to a combination of genetic and environmental factors.

Food Allergy Diagnosis

Food allergy is diagnosed primarily through clinical evaluation and detailed patient history, focusing on reproducible symptoms such as urticaria, gastrointestinal distress, respiratory difficulty, or anaphylaxis following food exposure. Diagnostic tests, including skin prick testing and serum-specific immunoglobulin E (IgE) measurements, help confirm sensitization, while oral food challenge remains the gold standard for definitive diagnosis.

Food Allergy Treatment

The primary goals of food allergy treatment are to prevent allergic reactions, reduce the risk of severe outcomes such as anaphylaxis, improve patient quality of life, and, where possible, induce long-term immune tolerance. Management is largely centered on strict allergen avoidance and patient education, including careful label reading and prevention of cross-contamination. Emergency preparedness is essential, with epinephrine (e.g., EpiPen, AUVI-Q) as the first-line treatment for anaphylaxis, supported by adjunctive therapies such as antihistamines (e.g., cetirizine, diphenhydramine) and corticosteroids for symptom control.

For long-term management, immunotherapy approaches are increasingly adopted in a step-wise manner. Oral immunotherapy (OIT), such as PALFORZIA, is used to achieve desensitization through controlled allergen exposure. Emerging alternatives include epicutaneous immunotherapy (EPIT) like Viaskin Peanut Patch (DBV712) and sublingual immunotherapy (SLIT), which offer improved safety profiles. In patients with severe or multiple food allergies, biologic therapies such as XOLAIR may be considered to target IgE-mediated pathways and enhance treatment outcomes. Supportive strategies, including dietary modification, regular monitoring, and management of comorbid allergic conditions, remain critical to ensure sustained protection and reduce the risk of recurrence.

Food Allergy Unmet Needs

The section "unmet needs of Food Allergy" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of curative therapies; current management relies on avoidance

2. Risk of severe reactions (anaphylaxis) and unpredictable triggers

3. Limitations in diagnostic accuracy and standardization, and others.....

Comprehensive unmet needs insights in Food Allergy and their strategic implications are provided in the full report.

Food Allergy Epidemiology

Key Findings from Food Allergy Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalent cases of Food Allergy in the 7MM were approximately 61,000,000 in 2025.
• Among the EU4 and the UK, Spain accounted for the highest number of diagnosed prevalent cases of Food Allergy, followed by Germany, whereas France accounted for the lowest number of cases in 2025.
• In 2025, among gender-specific cases of food allergy in 7 million individuals, males accounted for 53% while females made up 47%.
• In Japan in 2025, egg allergy had the highest diagnosed prevalence among food allergens, followed by milk allergy, while fish allergy had the lowest prevalence.

Food Allergy Drug Chapters & Competitive Analysis

The Food Allergy drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Food Allergy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Food Allergy therapeutics market.

Approved Therapies for Food Allergy

Omalizumab (XOLAIR): Novartis/ Roche

XOLAIR, developed by Novartis and Roche, is a monoclonal anti-IgE antibody that targets the underlying allergic pathway by binding to free IgE and preventing its interaction with receptors on mast cells and basophils. Initially approved for allergic asthma and chronic spontaneous urticaria, XOLAIR received US FDA approval in 2024 for the treatment of food allergy to reduce the risk of allergic reactions, including anaphylaxis, following accidental exposure to one or more foods. By lowering circulating IgE levels, it helps decrease hypersensitivity responses and provides a novel, mechanism-driven approach for food allergy management, reflecting its expanded clinical utility and significance in addressing an area of high unmet need.

Epinephrine /Adrenaline (NEFFY/ EURNEFFY): ARS Pharmaceuticals /ALK Abello /Alfresa Pharma

NEFFY/EURNEFFY, developed by ARS Pharmaceuticals and partnered with ALK-Abello and Alfresa Pharma for global commercialization, is a needle-free, intranasal formulation of epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis associated with food allergy. As a fast-acting sympathomimetic agent, epinephrine works by constricting blood vessels, relaxing airway muscles, and reducing swelling, thereby rapidly reversing life-threatening symptoms. NEFFY has gained regulatory approvals in key markets, including the US and Europe, offering a convenient and user-friendly alternative to traditional injectable auto-injectors, potentially improving adherence and timely administration during acute allergic emergencies.

Food Allergy Pipeline Analysis

Viaskin (DBV712) Peanut Patch: DBV Technologies

DBV712, developed by DBV Technologies, is an innovative epicutaneous immunotherapy designed for the treatment of peanut allergy. It delivers small, controlled amounts of peanut protein through the skin using a non-invasive patch, promoting immune tolerance while minimizing systemic exposure. This approach targets Langerhans cells in the epidermis to modulate the immune response without entering the bloodstream in significant quantities. DBV712 aims to reduce the risk of severe allergic reactions upon accidental exposure, offering a safer and more convenient alternative to oral immunotherapy, particularly for pediatric patients.

PVX108 (AVX-201): Aravax

PVX108, developed by Aravax, is an investigational peptide-based immunotherapy for peanut allergy designed to induce immune tolerance by targeting specific T-cell epitopes of peanut allergens. Unlike traditional allergen exposure approaches, it uses short synthetic peptides that do not cross-link IgE, thereby reducing the risk of allergic reactions during treatment. This targeted mechanism aims to modulate the immune response, promoting long-term desensitization while improving safety and tolerability. By addressing the underlying immune dysfunction, PVX108 has the potential to offer a disease-modifying approach for food allergy management.

Food Allergy Key Players, Market Leaders and Emerging Companies

• Novartis
• Roche
• ARS Pharmaceuticals
• ALK-Abello
• Alfresa
• Stallergenes Greer
• DBV Technologies
• Aravax
• Aquestive Therapeutics, and others

Food Allergy Drug Updates

• In February 2026, Aquestive Therapeutics announced that it received a Complete Response Letter (CRL) from the FDA on January 30, 2026, for the New Drug Application (NDA) seeking approval of ANAPHYLM (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds).
• In February 2026, according to Novartis' Q4 2025 presentation, initiation of the Phase III program for remibrutinib is anticipated in the second half of 2026.
• In August 2025, Stallergenes Greer announced to voluntarily discontinue PALFORZIA by July 31, 2026, not due to safety, quality, or efficacy concerns. The company will fulfill regulatory obligations and support a smooth transition for patients and healthcare providers.

Food Allergy Market Outlook

The food allergy market is undergoing a significant transformation, shifting from strict allergen avoidance and emergency management toward more proactive, disease-modifying therapeutic approaches. The emergence of novel immunotherapies such as PALFORZIA, Viaskin Peanut Patch (DBV712), and PVX108 (AVX-201) reflects a move toward targeted immune modulation aimed at inducing long-term tolerance rather than temporary desensitization. These advancements highlight mechanism-driven strategies focused on improving safety, reducing the risk of severe reactions, and enhancing patient adherence, thereby strengthening clinical confidence and reshaping the competitive landscape.

With the continued development of innovative pipeline candidates, including PVX108 (AVX-201), Viaskin Peanut Patch (DBV712), and ANAPHYLM (epinephrine sublingual film), the food allergy treatment landscape is evolving in line with other immune-mediated conditions where precision-based therapies are gaining traction. Additionally, biologics targeting key immune pathways, such as XOLAIR, are further expanding therapeutic possibilities. The United States currently represents the largest food allergy market, supported by higher awareness, improved diagnosis rates, strong regulatory support, and early adoption of novel therapies compared with Europe and other regions.

Overall, the introduction of differentiated therapies such as PALFORZIA, alongside emerging options like Viaskin Peanut Patch, PVX108, and ANAPHYLM, improving diagnostic practices, and rising awareness among patients and caregivers are expected to drive steady growth in the global food allergy market over the forecast period. This evolving landscape presents substantial commercial opportunities for both approved products and pipeline candidates, particularly as the field moves closer to achieving long-term disease control and improved quality of life for patients.

• According to estimates, the total Food Allergy market size in 7MM was approximately USD 3,500 million in 2025, with the United States accounting for the largest share, and the market is projected to grow at a significant CAGR through 2036.
• In 2025, among the EU4 and the UK, Germany held the largest market share, followed by the UK, while France accounted for the smallest share.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Food Allergy (2022-2036 Forecast)

The food allergy market comprises emergency pharmacologic treatments, allergen-specific immunotherapies, biologics, and supportive/non-drug approaches, each addressing distinct aspects of acute reaction management, desensitization, and long-term immune modulation.

• Allergen-specific immunotherapies: Products such as PALFORZIA and Viaskin Peanut Patch (DBV712) aim to desensitize patients through controlled allergen exposure, increasing tolerance thresholds while requiring careful monitoring for adverse events.
• Biologics: Therapies such as XOLAIR target IgE-mediated pathways, reducing allergic response severity and emerging as adjunctive or standalone options in food allergy management.

Emergency treatments and immunotherapies together form the current standard of care, while biologics and next-generation immunomodulatory therapies are shaping the future innovation landscape in food allergy.

Food Allergy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Food Allergy market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in food allergy is expected to vary across allergen avoidance strategies, emergency treatments, immunotherapies, and emerging disease-modifying agents. Currently available options, such as epinephrine for acute reactions and oral immunotherapy (e.g., peanut allergen products), demonstrate moderate uptake, while newer approaches, including epicutaneous patches and peptide-based immunotherapies, are anticipated to show progressive adoption, supported by improved safety profiles and better patient compliance. Their uptake is likely to be driven by the limitations of strict dietary avoidance and the persistent risk of accidental exposure, along with the burden of anxiety and reduced quality of life. In comparison, next-generation therapies targeting immune tolerance and novel delivery approaches are expected to witness gradual but steady uptake as clinical evidence strengthens and these therapies become increasingly integrated into treatment guidelines for diverse food allergy populations.

Food Allergy Therapies Price Scenario & Trends

Pricing and analogue assessment of Food Allergy therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Juvenile Food Allergy Approved Drugs

At a list price of approximately USD 890 per month in the US, PALFORZIA results in an estimated annual therapy cost of around USD 10,680.

Further details are provided in the final report....

Industry Experts and Physician Views on Food Allergy

To keep up with Food Allergy market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Food Allergy emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Food Allergy, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, University of Nottingham, and Japanese Red Cross Central Blood Institute, etc. were contacted. Their opinion helps understand and validate current and emerging Food Allergy therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Food Allergy.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Food Allergy, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Food Allergy, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Food Allergy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Food Allergy market.

Report Insights

• Food Allergy Patient Population Forecast
• Food Allergy Therapeutics Market Size
• Food Allergy Pipeline Analysis
• Food Allergy Market Size and Trends
• Food Allergy Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Food Allergy Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Food Allergy Treatment Addressable Market (TAM)
• Food Allergy Competitive Landscape
• Food Allergy Major Companies Insights
• Food Allergy Price Trends and Analogue Assessment
• Food Allergy Therapies Drug Adoption/Uptake
• Food Allergy Therapies Peak Patient Share analysis

Report Assessment

• Food Allergy Current Treatment Practices
• Food Allergy Unmet Needs
• Food Allergy Clinical Development Analysis
• Food Allergy Emerging Drugs Product Profiles
• Food Allergy Market Attractiveness
• Food Allergy Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Food Allergy market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Food Allergy?
• What are the disease risks, burdens, and unmet needs of Food Allergy? What will be the growth opportunities across the 7MM concerning the patient population with Food Allergy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Food Allergy? What are the current guidelines for treating Food Allergy in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Food Allergy market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology of Food Allergy

6. Food Allergy Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of Food Allergy by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of Food Allergy by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Food Allergy

• 7.1. Introduction
• 7.2. Symptoms
• 7.3. Foods with Allergies
• 7.4. Risk Factors for Food Allergy Development
• 7.5. Clinical Manifestations
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnosis Algorithm
  • 7.6.3. Diagnosis Guidelines

8. Treatment and Management

• 8.1. Algorithm for the Treatment of Food Allergy
• 8.2. Guidelines for the treatment of Food Allergy

9. Epidemiology and Patient Population of Food Allergy

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Diagnosed Prevalent Cases of Food Allergy in the 7MM
• 9.4. The United States
  • 9.4.1. Total Diagnosed Prevalent Cases of Food Allergy in the United States
  • 9.4.2. Allergen-specific Diagnosed Prevalent Cases of Food Allergy in the United States
  • 9.4.3. Gender-specific Diagnosed Prevalent Cases of Food Allergy in the United States
  • 9.4.4. Severity-specific Diagnosed Prevalent Cases of Food Allergy in the United States
  • 9.4.5. Total treated cases of Food Allergy in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Food Allergy in the EU4 and the UK
  • 9.5.2. Allergen-specific Diagnosed Prevalent Cases of Food Allergy in the EU4 and the UK
  • 9.5.3. Gender-specific Diagnosed Prevalent Cases of Food Allergy in the EU4 and the UK
  • 9.5.4. Severity-specific Diagnosed Prevalent Cases of Food Allergy in the EU4 and the UK
  • 9.5.5. Total treated cases of Food Allergy in the EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Food Allergy in Japan
  • 9.6.2. Allergen-specific Diagnosed Prevalent Cases of Food Allergy in Japan
  • 9.6.3. Gender-specific Diagnosed Prevalent Cases of Food Allergy in Japan
  • 9.6.4. Severity-specific Diagnosed Prevalent Cases of Food Allergy in Japan
  • 9.6.5. Total treated cases of Food Allergy in Japan

10. Patient Journey of Food Allergy

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Food Allergy
• 11.2. Omalizumab (XOLAIR): Novartis/ Roche
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. Epinephrine /Adrenaline (NEFFY/ EURNEFFY): ARS Pharmaceuticals /ALK/Alfresa
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Food Allergy
• 12.2. Viaskin (DBV712) Peanut Patch: DBV Technologies
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views
• 12.3. PVX108 (AVX-201): Aravax
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst's Views

13. Food Allergy: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Food Allergy
• 13.3. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
  • 13.3.2. Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptakes
• 13.4. Conjoint Analysis of Food Allergy
• 13.5. Total Market Size of Food Allergy in the 7MM
• 13.6. Total Market Size of Food Allergy by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of Food Allergy in the United States
  • 13.7.2. Total Market Size of Food Allergy by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of Food Allergy in EU4 and the UK
  • 13.8.2. Total Market Size of Food Allergy by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of Food Allergy in Japan
  • 13.9.2. Total Market Size of Food Allergy by Therapies in Japan

14. Unmet Needs of Food Allergy

15. SWOT Analysis of Food Allergy

16. KOL Views of Food Allergy

17. Market Access and Reimbursement of Food Allergy

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Food Allergy Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

• Table 1: Summary of Food Allergy: Market, Epidemiology, and Key Events (2022-2036)
• Table 2: Differential Diagnosis of Food Allergy
• Table 3: Total Diagnosed Prevalent Cases of Food Allergy in the 7MM (in thousands) (2022-2036)
• Table 4: Allergen-Specific Diagnosed Prevalent Cases of Food Allergy(in Thousands) in the 7MM (2022-2036)
• Table 5: Gender-Specific Diagnosed Prevalent Cases of Food Allergy(in Thousands) in the 7MM (2022-2036)
• Table 6: Severity-specific Diagnosed Prevalent Cases of Food Allergy(in Thousands) in the 7MM (2022-2036)
• Table 7: Viaskin (DBV712) Peanut Patch, Clinical Trial Description
• Table 8: PVX108 (AVX-201), Clinical Trial Description
• Table 9: 7MM Market Size of Food Allergy in USD Million (2022-2036)
• Table 10: 7MM Market Size of Food Allergy in USD Million (2022-2036)
• Table 11: The United States Market Size of Food Allergy in USD Million (2022-2036)
• Table 12: EU-4 & UK Market Size of Food Allergy by Therapies in USD Million (2022-2036)
• Table 13: Japan Market Size of Food Allergy by Therapies in USD Million (2022-2036)

List of Figures

• Figure 1: Symptoms of Food Allergy
• Figure 2: Risk Factors of Food Allergy
• Figure 3: Differential Diagnosis of Food Allergy
• Figure 4: Diagnostic Algorithm for Food Allergy
• Figure 5: Treatment Algorithm for Food Allergy
• Figure 6: Treatment Algorithm for Food Allergy
• Figure 7: Total Diagnosed Prevalent Cases of Food Allergy in the 7MM
• Figure 8: Allergen-Specific Diagnosed Prevalent Cases of Food Allergy in the 7MM (2022-2036)
• Figure 9: Gender-Specific Diagnosed Prevalent Cases of Food Allergy in the 7MM (2022-2036)
• Figure 10: Severity-specific Diagnosed Prevalent Cases of Food Allergy in the 7MM
• Figure 11: Market Size of Food Allergy in the 7MM, USD Million (2022-2036)
• Figure 12: 7MM Market Size of Food Allergy in USD Million (2022-2036)